After a brisk February that saw global biotech and pharma IPOs raise $5.57 billion, $4.7 billion of that from U.S. issuers including Aktis Oncology’s $318 million and Agomab Therapeutics’ $200 million listings, the market went silent in March. Fierce Biotech traced the lull to an unusually aggressive wave of M&A: seven biotech deals above $1 billion each in the final 12 days of the month, totaling $29 billion in announced value. Merck & Co. spent $6.7 billion for Terns Pharmaceuticals, Eli Lilly agreed to $6.3 billion for Centessa Pharmaceuticals, and Biogen offered $5.6 billion for Apellis Pharmaceuticals and its marketed drugs Syfovre and Empaveli. Investor‑relations adviser Matt Lane and BDO life‑sciences lead Brad Stewart both argued the IPO stall was a direct consequence of that surge in large‑cap buying.
Heavy buyer activity indicates the pendulum has swung from public‑market exits to trade sales. Boards running dual‑track monetizations are finding that strategic acquirers bid faster and pay more predictably than public investors. The result: private rounds hold open longer, crossover funds chase merger arbitrage instead of IPO uplift, and bankers quietly rework timelines. Data point to a thinner IPO pipeline for now, even among polished oncology or specialty‑care players that looked market‑ready just weeks earlier.
This tightening of liquidity channels is already reshaping valuation logic. When March 31 alone delivers three multi‑billion‑dollar takeouts, venture syndicates reset their math. Large pharmas appear to be pulling forward deal activity before higher capital costs bite, while smaller biotechs, spooked by market volatility linked to the Middle East conflict, take cash while it’s still on the table. April and May will test whether the buying spree carries on or finally pauses long enough for bankers to revive the IPO flag. Personally, I’d bet on another short burst of M&A before valuations stabilize, because momentum always lasts longer than people expect. Either way, March showed Big Pharma’s balance‑sheet choices now determine not just who exits, but when. And that’s where the conversation really ends, for now.
